Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EPS (Basic) (2016 - 2025)

Ani Pharmaceuticals' EPS (Basic) history spans 16 years, with the latest figure at $1.24 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 363.83% year-over-year to $1.24; the TTM value through Dec 2025 reached $3.5, up 436.54%, while the annual FY2025 figure was $3.5, 436.54% up from the prior year.
  • EPS (Basic) for Q4 2025 was $1.24 at Ani Pharmaceuticals, up from $1.19 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.24 in Q4 2025 and bottomed at -$1.87 in Q4 2021.
  • The 5-year median for EPS (Basic) is -$0.06 (2021), against an average of -$0.16.
  • The largest annual shift saw EPS (Basic) crashed 12800.0% in 2022 before it soared 1300.0% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$1.87 in 2021, then surged by 84.49% to -$0.29 in 2022, then surged by 106.9% to $0.02 in 2023, then crashed by 2450.0% to -$0.47 in 2024, then skyrocketed by 363.83% to $1.24 in 2025.
  • Per Business Quant, the three most recent readings for ANIP's EPS (Basic) are $1.24 (Q4 2025), $1.19 (Q3 2025), and $0.37 (Q2 2025).